All In Biotech

Drug Trial Radar · NCT03282227

A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine

A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine

Last checked: Nov 20, 2026Latest source record: Aug 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

342

Actual

Start

Nov 7, 2017

Primary completion

May 17, 2019

Study completion May 17, 2019

Sponsor

Lead sponsor
Zosano Pharma CorporationIndustry
Sponsor type
Industry
First posted
Sep 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, twelve-month safety study. There is a screening period followed by a run-in period to record migraine activity. Qualified subjects will receive study medication for up to twelve months for the treatment of multiple migraine attacks. Using the electronic diary (eDiary) to confirm they are experiencing a qualified migraine, subjects will self-administer the patches and respond to questions in the eDiary post treatment administration.

Conditions

  • Migraine

Interventions

  • M207 Microneedle SystemDrug

    M207 Microneedle System 3.8 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Any Treatment-emergent Adverse Events (TEAE) Over 12 MonthsTime frame: 0 to 12 months

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Achieve Clinical Research

    Birmingham, Alabama

  • Elite Clinical Studies

    Phoenix, Arizona

  • Downtown L.A. Research Center

    Los Angeles, California

  • Stanford University Medical Center

    Palo Alto, California

  • Allergy Asthma Associates of Santa Clara Valley Research Center

    San Jose, California

  • California Medical Clinic for Headache

    Santa Monica, California

  • Empire Clinical Research

    Upland, California

  • Colorado Allergy Asthma Centers

    Denver, Colorado

  • Harmony Medical Research Institute

    Hialeah, Florida

  • Advanced Clinical Research

    Meridian, Idaho

  • DelRicht Research

    New Orleans, Louisiana

  • Boston Clinical Trials

    Boston, Massachusetts

  • MedVadis Research Corporation

    Watertown, Massachusetts

  • Michigan Headache and Neurological Institute

    Ann Arbor, Michigan

  • Clinical Research Institute

    Minneapolis, Minnesota

  • Clinical Research Institute

    Plymouth, Minnesota

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri

  • Clinvest Research

    Springfield, Missouri

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

  • Albuquerque Clinical Trials

    Albuquerque, New Mexico

  • Rochester Clinical Research

    Rochester, New York

  • Peters Medical Research

    High Point, North Carolina

  • North Carolina Clinical Research

    Raleigh, North Carolina

  • Raleigh Medical Group PMG Research

    Raleigh, North Carolina

  • Lillestol Research

    Fargo, North Dakota

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Primary Care Associates/Radiant Research

    Anderson, South Carolina

  • Coastal Carolina Research Center

    Mt. Pleasant, South Carolina

  • FutureSearch Trials of Neurology

    Austin, Texas

  • University of Texas Southwestern Medical Center - Neurology Clinic

    Dallas, Texas

  • Central Texas Health Research

    New Braunfels, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.